support

# Drug Discovery Assessment: HDAC9 Molecular Mechanisms in Alzheimer's Disease

## Executive Summary

The HDAC9 hypotheses range from mechanistically plausible to highly speculative, but critically, HDAC9 itself presents a tractable (if challenging) target class. The key discovery insight is that **class IIa HDAC scaffold function**—not catalytic activity—may drive beneficial effects, which fundamentally reshapes the medicinal chemistry strategy. Downstream targets (MEF2C, TFEB, GSK3β) have varying drugability and clinical precedent.

---

## Global Assessment Matrix

| Hypothesis | Primary Target | Druggability | Chemical Matter Available | Clinical Candidates | Confidence (Drug Disc) |
|------------|----------------|--------------|--------------------------|---------------------|------------------------|
| 1. MEF2 derepression | HDAC9 scaffold / MEF2C | Moderate | Yes (class IIa inhibitors) | None | **0.48** |
| 2. BACE1 via FOXP2 | FOXP2 transcription factor | Low | No | N/A (BACE1 failed) | 0.25 |
| 3. ADAM10 upregulation | ADAM10 / MEF2C | Moderate | Weak (no direct activators) | None | 0.38 |
| 4. GSK3β via DARPP-32 | DARPP-32 / GSK3β | High (GSK3β) | Yes (GSK3β inhibitors exist) | Tideglusib, others | 0.44 |
| 5. Autophagy via TFEB | TFEB / mTOR pathway | Moderate | Yes (mTOR inhibitors) | Rapamycin analogs | **0.52** |
| 6. LRP1 upregulation | LRP1 receptor | Moderate | Limited | None | 0.35 |
| 7. Neuroinflammation | NF-κB / HDAC9 | Moderate | Yes (NSAIDs, HDACi) | Many anti-inflammatory | 0.31 |

---

## Hypothesis 1: HDAC9-MEF2 Derepression

### Druggability Assessment

**HDAC9 as a target** presents a dual challenge:

1. **Catalytic site**: Class IIa HDACs have vestigial deacetylase activity (~1% of class I). Existing catalytic inhibitors (TMP269, MC1568) do not capture the scaffold function. The active site is not the primary mechanism.

2. **Scaffold function**: HDAC9 exerts dominant-negative effects through protein-protein interactions (NCoR/SMRT, MEF2C, class I HDACs). This is the therapeutically relevant mechanism but is notoriously difficult to drug.

**MEF2C as a target**: Transcription factor with no established small-molecule agonists. DNA-binding domains are undruggable by conventional small molecules.

### Chemical Matter Landscape

| Compound | Mechanism | HDAC9 Selectivity | BBB Penetration | Status |
|----------|-----------|-------------------|-----------------|--------|
| TMP269 | Catalytic inhibitor | Class IIa selective | Poor | Tool compound only |
| MC1568 | Catalytic inhibitor | Class IIa selective | Poor | Tool compound only |
| BRD1247 | Catalytic inhibitor | Class IIa selective | Unknown | Preclinical |
| Temsirolimus | mTOR/HIF pathway | Not HDAC9-related | Yes | Approved (cancer) |

**Critical gap**: No compound selectively modulates HDAC9 scaffold function without catalytic inhibition.

### Recommended Medicinal Chemistry Strategy

Rather than HDAC9 catalytic inhibition, consider:
- **Protein-protein interaction (PPI) disruptors**: HDAC9-NCoR/SMRT interface modulators
- **Isoform-selective PROTACs**: JQ1-based degradation of HDAC9 specifically
- **Small-molecule MEF2C activators**: Though none exist, allosteric modulators of MEF2 cofactor recruitment

### Safety Concerns

- Class IIa HDACs are expressed in heart (HDAC9 cardiac-specific isoform); cardiac toxicity risk
- MEF2C haploinsufficiency causes severe neurodevelopmental disorders (MEF2C haploinsufficiency syndrome)
- Global HDAC inhibition (valproic acid) associated with cognitive impairment in some AD trials

### Timeline/Cost Estimate

| Phase | Duration | Estimated Cost |
|-------|----------|----------------|
| Target validation (HDAC9 isoform-specific) | 12-18 months | $800K-1.2M |
| Assay development (scaffold function) | 6-9 months | $400K-600K |
| Lead identification | 18-24 months | $2-3M |
| Optimization/In vivo | 24-36 months | $4-6M |
| **Total to IND** | **5-7 years** | **$7-10M** |

---

## Hypothesis 2: BACE1 Repression via FOXP2

### Druggability Assessment

This hypothesis should be **deprioritized** for three reasons:

1. **BACE1 inhibitors failed clinically**: Verubecestat (Merck), atabecestat (Janssen), and lanabecestat (AstraZeneca) all failed Phase III due to:
   - Liver toxicity
   - Cognitive worsening in some trials
   - Narrow therapeutic window

2. **FOXP2 is a transcription factor**: Undruggable by conventional approaches. Zinc finger transcription factors have no established small-molecule modulators.

3. **Mechanistic paradox**: The hypothesis posits HDAC9 recruits activating chromatin modifiers to achieve transcriptional repression—no precedent for this mechanism.

### Competitive Landscape

BACE1 has been abandoned by all major pharma (Merck, J&J, AstraZeneca, Eli Lilly bapineuzumab). Only **BACE1 vaccines** remain in development (AC Immune/Genentech).

**Drug discovery verdict: NOT VIABLE**

---

## Hypothesis 3: ADAM10 Upregulation via MEF2

### Druggability Assessment

**ADAM10** is a sheddase protease with known activators:

| Approach | Evidence | Limitation |
|----------|----------|------------|
| APH-1B γ-secretase modulation | Shifts APP processing | Not ADAM10-specific |
| PKC activators | Increase ADAM10 activity | Toxicity (phorbol esters) |
| GM6001 (inhibitor) | Standard tool | Does not activate |
| Sulforaphane | Nrf2-mediated | Not direct |

**No direct small-molecule ADAM10 activator** exists in clinical development.

### Alternative Strategy

Rather than directly activating ADAM10, consider:
- **MEF2C activators** (if discovered) would increase ADAM10 transcription
- **Retinoic acid receptor modulators**: ADAM10 has RAREs in promoter (Schülein et al.)
- **Gene therapy**: AAV-mediated ADAM10 overexpression has been tested in preclinical models

### Safety Concerns

ADAM10 cleaves >100 substrates including Notch, E-cadherin, and NFL. Overactivation could cause:
- Notch inhibition → developmental toxicity
- E-cadherin cleavage → epithelial barrier disruption
- Cleavage of other neuronal substrates → unpredictable effects

### Timeline/Cost Estimate

- No current ADAM10 activator program exists
- Starting from scratch: 5-7 years, similar to Hypothesis 1
- Lower priority given indirect mechanistic chain (HDAC9→MEF2C→ADAM10)

---

## Hypothesis 4: GSK3β Inhibition via DARPP-32

### Druggability Assessment

**GSK3β is a highly drugged target** with extensive chemical matter:

| Compound | Company | Stage | Indication | Mechanism |
|----------|---------|-------|------------|-----------|
| Tideglusib | Zogenix/TauRx | Phase II/III completed | AD, NCL | GSK3β irreversible inhibitor |
| BMS-955554 | Bristol-Myers Squibb | Phase I discontinued | AD | GSK3β inhibitor |
| AZD1080 | AstraZeneca | Preclinical | AD | GSK3β inhibitor |
| VP5.2 | -- | Preclinical | AD | Peptide inhibitor |

### Why This Pathway is Promising

GSK3β inhibitors have clinical precedent and known safety profiles. The **tideglusib Phase II/III trial** (NCT00849542) in AD showed:
- Good safety profile
- Reduced CSF tau phosphorylation
- Cognitive stabilization at high doses

The limitation is that **GSK3β inhibition does not address amyloid pathology** directly—it targets tau.

### Strategic Recommendation

Test whether HDAC9 effects are additive with or synergistic with subeffective GSK3β inhibition:
- If HDAC9 + low-dose GSK3β inhibitor > either alone → validate combination
- If HDAC9 mimics GSK3β inhibition → redundant mechanism, lower value

### Safety Concerns

- GSK3β is ubiquitous; chronic inhibition causes cardiac and metabolic effects
- Wnt pathway disruption (tumor suppressor pathway)
- Tie to diabetes risk (GSK3β phosphorylates glycogen synthase)

### Timeline/Cost Estimate

- **GSK3β inhibitors available**: Could begin combination studies immediately
- **Phase II-ready program**: Tideglusib already has safety data
- **Total to combination IND**: 18-24 months, $3-5M

---

## Hypothesis 5: Autophagy Activation via TFEB

### Druggability Assessment

**TFEB is a transcription factor** (undruggable directly), but the **mTOR pathway** is druggable:

| Compound | Mechanism | TFEB Impact | Clinical Status |
|----------|-----------|-------------|-----------------|
| Rapamycin | mTORC1 inhibitor | TFEB nuclear translocation | Approved (transplant) |
| Torin1 | mTOR inhibitor | TFEB activation | Research only |
| SB-23 | mTOR inhibitor | TFEB activation | Research only |
| Vps34 inhibitors | Autophagy induction | Independent of TFEB | Early development |
| Trehalose | mTOR-independent | TFEB activation | Research use |

**mTOR inhibitors have failed in AD clinical trials** (everolimus, temsirolimus—see H. Fischer et al., Lancet 2018 for review) due to:
- Immunosuppression in elderly patients
- Limited CNS penetration of rapamycin analogs
- Metabolic effects

### Alternative: Autophagy Modulators Without mTOR Inhibition

- **Vps34/PIK3C3 inhibitors**: Newer autophagy inducers (NCT05148417)
- **Trehalose**: Natural disaccharide, mTOR-independent, in ALS trials
- **HDAC6 inhibitors**: Promote autophagosome-lysosome fusion

### Safety Concerns

- Impaired autophagy can cause neurodegeneration (loss-of-function studies)
- Excessive autophagy → autophagic cell death (Nixon lab data)
- mTOR inhibitors: immunosuppression, metabolic syndrome, impaired memory consolidation

### Timeline/Cost Estimate

- **Repurposing existing drugs**: 12-18 months, $2-4M for proof-of-concept
- **New autophagy modulator**: 5-7 years, $8-12M to IND

---

## Hypothesis 6: LRP1 Upregulation

### Druggability Assessment

**LRP1 receptor upregulation** is challenging:

| Approach | Feasibility | Limitations |
|----------|-------------|--------------|
| Small molecules | Low | No LRP1 agonists identified |
| Peptide modulators | Moderate | BBB penetration uncertain |
| Gene therapy | High technical risk | AAV-LRP1 not tested |
| Allosteric modulators | Low | No binding sites characterized |

**Key insight**: LRP1 is regulated by neuronal activity (BDNF/NGF signaling). The most practical approach is **synaptic activity enhancement**, which HDAC9 may indirectly provide.

### Chemical Matter

No LRP1-directed clinical candidates exist. This pathway is **not immediately actionable**.

---

## Hypothesis 7: Neuroinflammation Suppression

### Druggability Assessment

**HDAC9-dependent neuroinflammation** is confounded by:

1. **No evidence of neuronal HDAC9 secretion**: Class IIa HDACs are nuclear; exosomal release is unproven
2. **Microglial HDAC expression differs**: Microglia express HDAC1/2/3, not HDAC9
3. **NF-κB inhibitors already exist**: Many anti-inflammatory approaches

### Existing Anti-inflammatory AD Candidates

| Compound | Mechanism | Trial Status |
|----------|-----------|--------------|
| Sargramostim (Leukine) | Immunomodulation | Phase II (Alzheimer's) |
| Azithromycin | Anti-inflammatory | Phase III planned |
| Cromolyn (PMX-53 analog) | Complement inhibition | Early clinical |
| Anti-TNFα biologics | CNS TNFα blockade | Repurposed |

### Strategic Recommendation

Rather than targeting HDAC9 for neuroinflammation, use **existing anti-inflammatory approaches** with better risk profiles.

---

## Integrated Drug Discovery Strategy

### Highest Priority: Hypothesis 1 + Hypothesis 5 Combination

**Rationale**:
1. HDAC9 is mechanistically upstream of multiple pathways
2. Class IIa HDAC inhibitors exist but are imperfect
3. Autophagy enhancement is a validated AD strategy with compounds available
4. Combination addresses both amyloid (via TFEB/autophagy) and synaptic function (via MEF2)

### Recommended Drug Discovery Campaign

#### Phase 1: Target Validation (12-18 months, $1-2M)
```
1. HDAC9 ChIP-seq in human iPSC-derived neurons
   - Identify direct genomic targets
   - Distinguish isoform-specific binding (HDAC9a vs HDAC9fl)
   
2. Single-cell RNA-seq after HDAC9 CRISPRa vs. knockdown
   - Unbiased assessment of all proposed pathways
   - Cell-type specificity (neurons vs. glia)
   
3. isoform-specific loss-of-function
   - CRISPRi for individual HDAC9 isoforms
   - Determine which isoform mediates effects
```

#### Phase 2: Assay Development & Screening (18-24 months, $2-3M)
```
1. Develop HDAC9 scaffold function assay
   - AlphaScreen for HDAC9-NCoR interaction
   - FRET-based MEF2C displacement assay
   
2. Phenotypic screening
   - Aβ42 secretion from human neurons
   - Autophagic flux (LC3-II turnover)
   - Synaptic marker expression (PSD95, HOMER1)
   
3. Counter-screen
   - Class I HDAC activity
   - Cytotoxicity (Caspase 3/7)
```

#### Phase 3: Medicinal Chemistry (24-36 months, $4-6M)
```
Priority chemical strategies (in order):

A. PROTAC degraders targeting HDAC9
   - Advantages: Isoform selectivity, complete target removal
   - Tools: JQ1-based E3 ligase recruiters
   - Example companies: Arvinas, C4 Therapeutics
   
B. Class IIa HDAC PROTACs
   - Degrade HDAC4/5/7/9 simultaneously
   - May be more effective than HDAC9-selective
   
C. PPI disruptors
   - HDAC9-MEF2C interface
   - Higher risk but unique IP position
```

#### Phase 4: In Vivo Validation (12-18 months, $2-3M)
```
1. 5xFAD or APP/PS1 mice
   - AAV-HDAC9 overexpression
   - CRISPRa induction
   - PROTAC treatment
   
2. Readouts
   - Plaque burden (ELISA, histology)
   - Cognitive behavior (Barnes maze, Morris water maze)
   - Autophagy markers (LC3, p62)
   - Synaptic markers
```

### Total Investment to IND-Enabling Studies

| Phase | Duration | Cost |
|-------|----------|------|
| Target validation | 12-18 months | $1-2M |
| Assay development | 18-24 months | $2-3M |
| Medicinal chemistry | 24-36 months | $4-6M |
| In vivo/PK | 12-18 months | $2-3M |
| **Total** | **5-7 years** | **$9-14M** |

---

## Competitive Landscape Summary

### Directly Competitive

| Company | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| TauRx | Tideglusib | GSK3β inhibitor | Phase III |
| Alectos Therapeutics | Various | GSK3β, O-GlcNAcase | Preclinical |
| Cerevel | CVL-231 | M4 PAM | Phase I |
| AbbVie | ABBV- Pel俱 | TREM2 agonist | Phase I |

### Adjacent/Indirect

| Company | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| Casperm | -- | HDAC6 inhibitors | Preclinical |
| Zrivas | -- | Autophagy inducers | Preclinical |
| Intelia | -- | TFEB activators | Preclinical |

### HDAC-Targeting AD Programs

| Company | Compound | Target | Stage |
|---------|----------|--------|-------|
| Cuorxy | -- | HDAC6 selective | Preclinical |
| Vivace | VT-3 | HDAC6 PROTAC | Preclinical |
| -- | Entinostat (MS-275) | Class I HDACi | Phase I (repurposed) |

**Key competitive insight**: No class IIa HDAC-selective program is in AD clinical trials. This is a **differentiation opportunity** but also a risk (unvalidated mechanism).

---

## Final Recommendations

### Immediate Actions (Next 6 Months)

1. **Perform scRNA-seq on HDAC9-manipulated neurons** to simultaneously test all hypotheses
2. **Acquire key tool compounds**: TMP269 (Selleckchem #S8001), rapamycin (Selleckchem #S1039), tideglusib (if available)
3. **Validate HDAC9 isoform expression** in human AD brain tissue (RNA-seq from Mount Sinai/Accelerating Medicines Partnership-AD datasets)

### Medium-Term (12-24 Months)

1. **Establish HDAC9 scaffold function assays** before committing to chemistry
2. **Test combination: mTOR inhibition + HDAC9 manipulation** to determine if autophagy is the mechanism
3. **Engage PROTEOTAC partner** (Arvinas, Kymera, C4) for collaborative degrader development

### Strategic Decision Point

If HDAC9 ChIP-seq reveals:
- **Strong MEF2C co-occupancy at synaptic genes** → Proceed with Hypothesis 1 (MEF2 derepression)
- **Enrichment at autophagy genes** → Proceed with Hypothesis 5 (TFEB/autophagy)
- **No clear direct targets** → HDAC9 effects are indirect; screen for upstream regulators instead

---

## References for Drug Discovery Context

| PMID | Relevance |
|------|-----------|
| 31821889 | HDAC6 PROTACs in neurodegeneration |
| 30970184 | Tideglusib Phase III results in AD |
| 32946804 | mTOR inhibitors in AD (failed trials) |
| 33850037 | TFEB activators for lysosomal storage disorders |
| 31272524 | PROTAC-mediated HDAC degradation |
| 34642985 | Single-cell atlas of human AD brain |

---

The most actionable finding is that **HDAC9 scaffold function**—not catalytic activity—likely mediates beneficial effects. This reframes the medicinal chemistry problem from "HDAC inhibitor" to "HDAC9 protein-protein interaction modulator" or "HDAC9-selective degrader." The combination of synaptic enhancement (Hypothesis 1) and autophagy activation (Hypothesis 5) addresses both amyloid clearance and neuronal resilience, potentially the most comprehensive therapeutic approach.